A Growing
Library

Publications

ASH 2019 Publications

      • Barr P, et. al. A Phase 1/2 Study of Umbralisib, Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). American Society of Hematology (ASH) 12.8.2019
      • Cheah C, et. al. Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies. American Society of Hematology (ASH) 12.9.2019

Sort

Sort All Publications

PublishedTitleLead AuthorDrugConferenceDownloadcategories_hfilter
September 23, 2019Phase I/II Triple Therapy Study of Umbralisib and Ublituximab (U2) Combined with Checkpoint Inhibition in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter’s Transformation (RT)Mato A, et. al.umbralisib (TGR-1202), ublituximab (TG-1101)International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Download

2019 iwcll tg-1101 tgr-1202 year conferences drug
September 23, 2019A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor TherapyMato A, et. al.umbralisib (TGR-1202)International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Download

2019 iwcll tgr-1202 year conferences drug
September 12, 2019Study Design and Patient Demographics of the ULTIMATE Phase III Trials Evaluating Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)Cree B, et. al.ublituximab (TG-1101)European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Download

2019 ectrims tg-1101 year conferences drug
September 12, 2019Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)Fox E, et. al.ublituximab (TG-1101)European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Download

2019 ectrims tg-1101 year conferences drug
July 12, 2019Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)Fox E, et. al.ublituximab (TG-1101)5th Congress of the European Academy of Neurology (EAN)

Download

2019 ean tg-1101 year conferences drug
June 20, 2019A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor TherapyMato A, et. al.umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2019 icml tgr-1202 year conferences drug
June 20, 2019Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s TransformationMato A, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2019 icml tg-1101 tgr-1202 year conferences drug
June 19, 2019Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 StudyZinzani P, et. al.umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2019 icml tgr-1202 year conferences drug
June 14, 2019The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHLRibeiro M et. al.TG-1801Congress of the European Hematology Association (EHA)

Download

2019 eha tg_1801 year conferences drug
June 9, 2019The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHLRibeiro M et. al.TG-1801, ublituximab (TG-1101), umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2019 icml tg_1801 tg-1101 tgr-1202 year conferences drug
June 4, 2019Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/ refractory marginal zone lymphoma: a multicenter, open-label, registration directed phase 2 studyFowler N, et. al.umbralisib (TGR-1202)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2019 asco tgr-1202 year conferences drug
May 7, 2019Open Label Extension (OLE) of a Phase 2 Multicenter Study Of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients With Relapsing Forms of Multiple Sclerosis (RMS)Fox E, et. al.ublituximab (TG-1101)American Academy of Neurology Annual Meeting (AAN)

Download

2019 aan tg-1101 year conferences drug
April 1, 2019TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual MeetingFowler N, et. al.umbralisib (TGR-1202)American Association for Cancer Research Annual Meeting (AACR)

Download

2019 aacr tgr-1202 year conferences drug
February 28, 2019Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis (RMS)Fox E, et. al.ublituximab (TG-1101)Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Download

2019 actrims tg-1101 year conferences drug
February 28, 2019Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis (RMS)Fox E, et. al.umbralisib (TGR-1202)Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Download

2019 actrims tgr-1202 year conferences drug
December 3, 2018TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and ExpositionLunning M, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2018 ash tg-1101 tgr-1202 year conferences drug
December 2, 2018Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s TransformationMato A, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2018 ash tg-1101 tgr-1202 year conferences drug
October 11, 2018Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)Fox E, et. al.ublituximab (TG-1101)European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Download

2018 ectrims tg-1101 year conferences drug
June 18, 2018Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered AntiCD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)Fox E, et. al.ublituximab (TG-1101)5th Congress of the European Academy of Neurology (EAN)

Download

2018 ean tg-1101 year conferences drug
June 16, 2018A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor TherapyMato A, et. al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2018 eha tgr-1202 year conferences drug
June 16, 2018Resurrecting response to ruxolitinib: A Phase I study of ruxolitinib and umbralisib (TGR-1202) in ruxolitinib-experienced myelofibrosisMoyo et al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2018 eha tgr-1202 year conferences drug
June 15, 2018TG-1701 is a novel, orally available and covalently bound BTK inhibitorNormant, E et. alTG-1701Congress of the European Hematology Association (EHA)

Download

eha tg_1701 conferences drug
June 15, 2018Long Term Integrated Safety Analysis Of Umbralisib (TGR-1202), A PI3K?/Ck1? Inhibitor With A Differentiated Safety Profile, In Patients With Relapsed/Refractory Lymphoid MalignanciesDavids M, et al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2018 eha tgr-1202 year conferences drug
June 4, 2018A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in patients with CLL who are intolerant to prior BTK or PI3K inhibitor therapyMato A, et. al.umbralisib (TGR-1202)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2018 asco tgr-1202 year conferences drug
April 24, 2018Final MRI Results at 6 Months from a Phase 2 Multicenter Study of Ublituximab, A Novel Glyocoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing LesionsInglese M, et. al.ublituximab (TG-1101)American Academy of Neurology Annual Meeting (AAN)

Download

2018 aan tg-1101 year conferences drug
April 18, 2018TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in pre-clinical modelsNormant, E et. alTG-1601American Association for Cancer Research Annual Meeting (AACR)

Download

2018 aacr tg_1601 year conferences drug
February 1, 20186 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple SclerosisFox E, et. al.ublituximab (TG-1101)Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Download

2018 actrims tg-1101 year conferences drug
December 11, 2017PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte DifferentiationFriedman, D et. alumbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2017 ash tgr-1202 year conferences drug
December 11, 2017An Integrated Safety Analysis of the Next Generation PI3K Delta Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid MalignanciesDavids M, et al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2017 ash tgr-1202 year conferences drug
December 11, 2017KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor TherapyMato A, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2017 ash tgr-1202 year conferences drug
December 10, 2017Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine ModelMaharaj, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2017 ash tgr-1202 year conferences drug
December 10, 2017Umbralisib/TGR-1202 as a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive LymphomasO'Connor, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2017 ash tgr-1202 year conferences drug
December 10, 2017Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLLMato A, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2017 ash tg-1101 tgr-1202 year conferences drug
October 27, 2017Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsetsLovett-Racke A, Fox E et. al.ublituximab (TG-1101)European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Download

2017 ectrims tg-1101 year conferences drug
October 26, 2017Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decreaseInglese M, et. al.ublituximab (TG-1101)European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Download

2017 ectrims tg-1101 year conferences drug
October 26, 2017Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosisFox E, et. al.ublituximab (TG-1101)European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Download

2017 ectrims tg-1101 year conferences drug
June 24, 2017Combination of TGR-1202, Ublituximab, and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphomaLunning M, et. al.ublituximab (TG-1101)Congress of the European Hematology Association (EHA)

Download

2017 eha tg-1101 tgr-1202 year conferences drug
June 24, 2017Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHLNastoupil L, et al.ublituximab (TG-1101), umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2017 eha tg-1101 tgr-1202 year conferences drug
June 24, 2017Rapid and Robust B Cell Depletion in Preliminary Results of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing forms of Multiple Sclerosis (RMS)Fox E, et. al.ublituximab (TG-1101)5th Congress of the European Academy of Neurology (EAN)

Download

2017 ean tg-1101 year conferences drug
June 16, 2017Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHLNastoupil L, et al.ublituximab (TG-1101), umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2017 icml tg-1101 tgr-1202 year conferences drug
June 16, 2017Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 studyMato A, et. al.ublituximab (TG-1101)International Congress on Malignant Lymphoma (ICML)

Download

2017 icml tg-1101 year conferences drug
June 15, 2017Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular LymphomaLunning M, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2017 icml tg-1101 tgr-1202 year conferences drug
June 14, 2017TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant LymphomaDavids M, et al.umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2017 icml tgr-1202 year conferences drug
June 5, 2017Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHLNastoupil L, et al.ublituximab (TG-1101), umbralisib (TGR-1202)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2017 asco tg-1101 tgr-1202 year conferences drug
June 3, 2017Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 studySharman J, et. al.ublituximab (TG-1101)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2017 asco tg-1101 year conferences drug
May 26, 2017Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, RMS PatientsLovett-Racke A, Fox E et. al.ublituximab (TG-1101)Annual Meeting of Consortium of MS Centers (CMSC)

Download

2017 cmsc tg-1101 year conferences drug
May 15, 2017TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL: Updated Results of a Multicenter Phase I/Ib StudyDavids M, et al.umbralisib (TGR-1202)International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Download

2017 iwcll tgr-1202 year conferences drug
May 15, 2017TGR-1202– A novel PI3K-delta inhibitor that differentially regulates T cells in CLLPinilla-Ibarz, et. al.umbralisib (TGR-1202)International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Download

2017 iwcll tgr-1202 year conferences drug
April 28, 2017Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletionLovett-Racke A, Fox E et. al.ublituximab (TG-1101)American Academy of Neurology Annual Meeting (AAN)

Download

2017 aan tg-1101 year conferences drug
April 4, 2017Preclinical Characterization of a Fully Human lgG1 Anti PD-L1 mab CK-301Marasco W, Gorelik L, et alanti PD-L1American Association for Cancer Research Annual Meeting (AACR)

Download

2017 aacr anti_pd_l1 year conferences drug
March 5, 2017KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapyDorsey, Mato, et. al.umbralisib (TGR-1202)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2017 asco tgr-1202 year conferences drug
February 21, 2017Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialSharman, Burke et. al.ublituximab (TG-1101)British Journal of Haematology (BJH)

Download

2017 bjh tg-1101 year conferences drug
December 16, 2016et. al. A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximabSawas, O'Connor et. al.ublituximab (TG-1101)British Journal of Haematology (BJH)

Download

2016 bjh tg-1101 year conferences drug
December 5, 2016TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study.Davids M, et al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2016 ash tgr-1202 year conferences drug
December 5, 2016Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3K Delta Inhibitor TGR-1202 in Myelofibrosis.Moyo et al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2016 ash tgr-1202 year conferences drug
December 5, 2016A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins LymphomaRamchandran et al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2016 ash tgr-1202 year conferences drug
December 5, 2016Combination of Ublituximab, TGR-1202 and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma.Lunning M, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2016 ash tgr-1202 year conferences drug
December 4, 2016Silencing cMyc Translation as a Therapeutic Strategy Through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies.Deng C, et.al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2016 ash tgr-1202 year conferences drug
December 4, 2016Modulation of T cell Compartment in a Preclinical CLL Murine Model by a Selective PI3K delta inhibitor, TGR-1202.Maharaj, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2016 ash tgr-1202 year conferences drug
October 27, 2016Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological MalignanciesDeng C, O'Connor O, et. al.umbralisib (TGR-1202)Blood Medical Journal - published by the American Society of Hematology (Blood)

Download

2016 blood tgr-1202 year conferences drug
September 14, 2016Open Label Safety Study of Ublituximab for the Treatment of Acute Neuromyelitis Optica RelapsesLevy M, Mealy M, et. Al.ublituximab (TG-1101)European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Download

2016 ectrims tg-1101 year conferences drug
June 3, 2016Long-term follow-up of the PI3K delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.Burris H, Flinn I, et. al.umbralisib (TGR-1202)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2016 asco tgr-1202 year conferences drug
June 1, 2016Preliminary Results of a Phase I/Ib Study of Ibrutinib in Combination with TGR-1202 in Patients with Relapsed/Refractory CLL or MCL.Davids M, et al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2016 eha tgr-1202 year conferences drug
June 1, 2016Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and commbined with ublituximab.Mato A, et. al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2016 eha tgr-1202 year conferences drug
June 1, 2016Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: INtegrated Analysi sof TGR-1202 monotherapy and combined with ublituximab.O'Connor O, et. al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2016 eha tgr-1202 year conferences drug
April 16, 2016Differential Regulation of Human T cells by TGR-1202, A Novel PI3K-delta Inhibitor.Pinilla-Ibarz, et. al.umbralisib (TGR-1202)American Association for Cancer Research Annual Meeting (AACR)

Download

2016 aacr tgr-1202 year conferences drug
December 8, 2015a Novel Once Daily PI3K- Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma.O'Connor O, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2015 ash tgr-1202 year conferences drug
December 8, 2015a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia.Mahadevan D, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2015 ash tgr-1202 year conferences drug
December 8, 2015Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas.Deng C, et.al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2015 ash tgr-1202 year conferences drug
December 8, 2015Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.Sharman J, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2015 ash tg-1101 year conferences drug
December 5, 2015Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.SharmanJ, et. Al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2015 ash tg-1101 year conferences drug
September 9, 2015a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL.O'Brien, et. al.umbralisib (TGR-1202)International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Download

2015 iwcll tgr-1202 year conferences drug
June 20, 2015a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma.O'Connor, et. al.umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2015 icml tgr-1202 year conferences drug
June 20, 2015The Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies.Nastoupil L, et al.ublituximab (TG-1101)International Congress on Malignant Lymphoma (ICML)

Download

2015 icml tg-1101 year conferences drug
June 20, 2015Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL.Burke J, et. al.ublituximab (TG-1101)International Congress on Malignant Lymphoma (ICML)

Download

2015 icml tg-1101 year conferences drug
June 20, 2015Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.Lunning M, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2015 icml tg-1101 tgr-1202 year conferences drug
June 14, 2015a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with CLL and B-Cell Lymphoma.O'Connor, et. al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2015 eha tgr-1202 year conferences drug
June 14, 2015Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.Lunning M, et. al.ublituximab (TG-1101)Congress of the European Hematology Association (EHA)

Download

2015 eha tg-1101 year conferences drug
June 2, 2015Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily Pi3k Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma.Burris H, Flinn I, et. al.umbralisib (TGR-1202)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2015 asco tgr-1202 year conferences drug
June 2, 2015Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.Lunning M, O'Brien S, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2015 asco tg-1101 tgr-1202 year conferences drug
June 2, 2015Safety and Activity of the Chemotherapy-free Triplet of Ublituximab, TGR-1202 and ibrutinib in Relapsed B-cell Malignancies.Fowler N, O'Brien S, et al.ublituximab (TG-1101)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2015 asco tg-1101 year conferences drug
April 18, 2015IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas.Vajda E, Marschke K, et. al.IRAK4American Association for Cancer Research Annual Meeting (AACR)

Download

2015 aacr irak4 year conferences drug
March 8, 2015Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results.Lunning M, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2015 ash tg-1101 tgr-1202 year conferences drug
December 9, 2014The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts.Locatelli, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2014 ash tgr-1202 year conferences drug
December 9, 2014Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma.Deng C, O'Connor O, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2014 ash tgr-1202 year conferences drug
December 9, 2014Ublituximab (TG-1101) a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL: Results of a Phase II Trial.Sharman J, Greenwald D, et.al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2014 ash tg-1101 year conferences drug
July 21, 2014A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin’s Lymphoma.Lunning M, O'Brien S, et. al.ublituximab (TG-1101)Pan Pacific Lymphoma Conference (PPLC)

Download

2014 pplc tg-1101 year conferences drug
June 13, 2014a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.Burris H, Flinn I, et. al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2014 eha tgr-1202 year conferences drug
June 13, 2014Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial.Sharman J, O'Connor O, et. al.ublituximab (TG-1101)Congress of the European Hematology Association (EHA)

Download

2014 eha tg-1101 year conferences drug
June 13, 2014Ublituximab (TG-1101), A Novel Anti-CD20 Monoclonal Antibody for Rituximab Relapsed/Refractory B-Cell Malignancies.O'Connor O, Farber C, et. al.ublituximab (TG-1101)Congress of the European Hematology Association (EHA)

Download

2014 eha tg-1101 year conferences drug
May 30, 2014A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab.Changchun D, O'Connor O, et. al.ublituximab (TG-1101)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2014 asco tg-1101 year conferences drug
May 30, 2014Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.Burris H, Flinn I, et. al.umbralisib (TGR-1202)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2014 asco tgr-1202 year conferences drug
April 9, 2014The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.Locatelli S, Carlo-Stella C, et. al.umbralisib (TGR-1202)American Association for Cancer Research Annual Meeting (AACR)

Download

2014 aacr tgr-1202 year conferences drug
April 9, 2014The PI3K Delta Inhibitor TGR-1202 Induces Cytotoxicity and Inhibits Phosphorylation of AKT in 17p Deleted and Non-17p Deleted CLL Cells in Vitro.Friedman D, Lanasa M, et. al.umbralisib (TGR-1202)American Association for Cancer Research Annual Meeting (AACR)

Download

2014 aacr tgr-1202 year conferences drug
March 9, 2014a Novel Once Daily Pi3K Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma.Burris H, Flinn I, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2014 ash tgr-1202 year conferences drug
March 9, 2014Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma.Lunning M, O'Brien S, et. al.ublituximab (TG-1101), umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2014 ash tg-1101 tgr-1202 year conferences drug
December 10, 2013A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies.Savona M, Patel M, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2013 ash tgr-1202 year conferences drug
December 10, 2013The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.Locatelli S, and Carlo-Stella C, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2013 ash tgr-1202 year conferences drug
December 10, 2013The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib are Highly Synergistic in Killing Human B- and T-Cell Lymphoma Cells.Deng C, O'Connor O, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2013 ash tgr-1202 year conferences drug
September 9, 2013The PI3k-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro.Friedman D, Lanasa M, et. al.umbralisib (TGR-1202)American Association for Cancer Research Annual Meeting (AACR)

Download

2013 aacr tgr-1202 year conferences drug
June 14, 2013A Novel, PI3K-Delta Specific Inhibitor in Multiple Myeloma.Vakkalanka S, Viswanadha S, et. al.umbralisib (TGR-1202)Congress of the European Hematology Association (EHA)

Download

2013 eha tgr-1202 year conferences drug
June 14, 2013Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies.Changchun D, O'Connor O, et. al.ublituximab (TG-1101)Congress of the European Hematology Association (EHA)

Download

2013 eha tg-1101 year conferences drug
June 4, 2013Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).Cazin B, Ribrag V, et. al.ublituximab (TG-1101)Congress of the European Hematology Association (EHA)

Download

2013 eha tg-1101 year conferences drug
June 2, 2013A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients.Changchun D, O'Connor O, et. al.ublituximab (TG-1101)American Society of Clinical Oncology Annual Meeting (ASCO)

Download

2013 asco tg-1101 year conferences drug
June 1, 2013Novel PI3K? Inhibitor TGR-1202 Demonstrates Cytotoxicity in B- and T-Cell Lymphoma Models and Is Synergistic with A Novel Anti-CD20 mAb, Ublituximab, in Models of LymphomaDeng, Changchunumbralisib (TGR-1202)International Congress on Malignant Lymphoma (ICML)

Download

2013 icml tgr-1202 year conferences drug
March 10, 2013Combined Carfilzomib and Selective PI3K-d Inhibition (TGR-1202) Results in Enhanced Myeloma Cell Apoptosis.Torre C, Lonial S, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2013 ash tgr-1202 year conferences drug
December 11, 2012Novel PI3K Inhibitors Demonstrated Marked Cytotoxicity in T Cell Lymphoma Models, Caused Apoptosis and Were Synergistic with A Novel Anti-CD20 Monoclonal Antibody Ublituximab in B Cell Lymphoma Models.Changchun D, O'Connor O, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2012 ash tgr-1202 year conferences drug
December 11, 2012Comparison of the PI3K-delta Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro.Friedman D, Lanasa M, Weinberg B,et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2012 ash tgr-1202 year conferences drug
December 11, 2012Suppresses AML and ALL Cells Via Selective Inhibition of PI3K-delta Kinase.Savona M, Vakkalanka S, et. al.umbralisib (TGR-1202)American Society of Hematology Annual Meeting (ASH)

Download

2012 ash tgr-1202 year conferences drug
December 11, 2012Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom’s Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab.Le Garff-Tavernier M, Leblond V, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2012 ash tg-1101 year conferences drug
December 11, 2012Ublituximab (TGTX-1101), a Novel, Third-Generation Anti-CD20 Antibody Demonstrates Enhanced Antitumor Activity Compared to Rituximab in Primary CNS and Intraocular Lymphoma Murine Models.Donnou S, Fisson S, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2012 ash tg-1101 year conferences drug
December 11, 2012Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-clinical In Vitro and In Vivo Models.Barth M, Czuczman M, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2012 ash tg-1101 year conferences drug
April 4, 2012Inhibition of PI3Kd kinase by a selective small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth.Vakkalanka S, Viswanadha S, et. al.umbralisib (TGR-1202)American Association for Cancer Research Annual Meeting (AACR)

Download

2012 aacr tgr-1202 year conferences drug
December 13, 2011LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody Displays An Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models.Tourais Esteves I, Fournès B, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2011 ash tg-1101 year conferences drug
December 13, 2011TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20.Echelard Y, Meade HM, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2011 ash tg-1101 year conferences drug
December 13, 2011Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).Cazin B, Coiffier B, Cartron G, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2011 ash tg-1101 year conferences drug
December 13, 2011Comparison of Cell Lysis Mediated by LFB-R603 with That Mediated by Ofatumumab Against Cells Expressing Low Levels of CD20.Bellon A, Salcedo M, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2011 ash tg-1101 year conferences drug
December 7, 2010A Phase I study of LFB-R603, a Novel Anti-CD20 Antibody, in Patients with Relapsed Chronic Lymphocytic Leukemia.Cartron G, Cazin B, et. al.ublituximab (TG-1101)American Society of Hematology Annual Meeting (ASH)

Download

2010 ash tg-1101 year conferences drug